PipelineReview.com4h
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment ...
PipelineReview.com4h
Solu Therapeutics Presents Positive Preclinical Data on STX-0712 for Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting
When combined with venetoclax and azacitidine (standard-of-care treatments for AML), STX-0712 improved therapeutic efficacy in 60% of patient samples by differential targeting both CCR2-positive ...
PipelineReview.com4h
Auron Presents New Preclinical Data for AUTX-703 in AML at ASH Annual Meeting
Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model ...
PipelineReview.com4h
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy ...
PipelineReview.com4h
MTTI 225Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors
WEST CHESTER, PA, USA I 09, 2024 I Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ...
PipelineReview.com8h
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
SUZHOU, China I 8, 2024 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and ...